Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.68 |
| ▸ | RAB9A | P51151 | 9/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | HPGD | P15428 | 4/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.67 |
| ▸ | TP53 | P04637 | 4/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | SI | P14410 | 1/20 | 0.61 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417301 | 0.88 | NPC1 (0.78) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL28027557 | 0.86 | KDM4E (0.75) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL17470481 | 0.83 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24075328 | 0.82 | KDM4E (0.62) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31592930 | 0.82 | GAA (0.47) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL31289464 | 0.81 | MEN1 (0.61) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL7270897 | 0.81 | CYP11B1 (0.58) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL30104615 | 0.81 | ALDH1A1 (0.68) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL3333857 | 0.81 | ALDH1A1 (0.54) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL26753825 | 0.81 | MGAM (0.52) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-01-14 | — | — | US | disclosed |
| WO-2024137505-A2 | METHOD OF IMPROVING CELL FITNESS IN AN EX-VIVO CELL POPULATION | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024118936-A1 | 2-ARYLBENZIMIDAZOLE COMPOUNDS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | TRANQUIS THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-114989094-B | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2023-09-29 | — | — | CN | disclosed |
| CN-112438977-B | Myricetin derivative containing benzimidazole, preparation method and application | 贵州大学 | 2023-05-19 | — | — | CN | disclosed |
| CN-112194654-B | Benzimidazole-containing myricetin derivative, preparation method and application | 贵州大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-114989094-A | Method for synthesizing benzimidazole derivative by visible light catalysis | 云南民族大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-30 | — | — | US | disclosed |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| CN-112438977-A | Benzimidazolium-containing myricetin derivative, preparation method and application | 贵州大学 | 2021-03-05 | — | — | CN | disclosed |
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2020033359-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-02-13 | — | — | WO | disclosed |
| CN-109468659-A | The method of room temperature synthesizing benzimidazole under the conditions of electrocatalytic method water phase | 云南师范大学 | 2019-03-15 | — | — | CN | disclosed |
| CN-109456273-A | The method of benzenecarboximidamide class compound synthesis benzimidazole compound is used in microwave method water phase | 云南师范大学 | 2019-03-12 | — | — | CN | disclosed |
| EP-3197450-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046130-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-03-31 | — | — | WO | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299244-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | NPC1 379/4885RAB9A 1910/4885SMN1; SMN2 593/4885 |
| US-20210300877-A1 | 2-ARYLBENZIMIDAZOLES AS PPARGC1A ACTIVATORS FOR TREATING NEURODEGENERATIVE DISEASES | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885SMN1; SMN2 39/4885 |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | NPC1 1303/4885RAB9A 1758/4885SMN1; SMN2 4153/4885 |
| US-11111217-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 502/4885RAB9A 2015/4885SMN1; SMN2 472/4885 |
| US-12195432-B2 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | PPARG, PPARA, PPARD | NPC1 989/4885RAB9A 2214/4885SMN1; SMN2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.